Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, and sales of Sodium Hyaluronate, focusing on Medical and Pharmaceutical Grade HA.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Menu

    Olmutinib

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GSK poaches New Drug-dev chief from Boehringer, dividing R&D into 2 groups
    GSK poaches New Drug-dev chief from Boehringer, dividing R&D into 2 groups

    19 Sep 2018

    // John Carroll ENDPTS

    https://endpts.com/gsk-poaches-new-drug-development-chief-chris-corsico-from-boehringer-ingelheim/

    John Carroll ENDPTS
    19 Sep 2018
    Share Share
    After patient deaths, failed partnerships & scandal, Hanmi gives up olmutinib
    After patient deaths, failed partnerships & scandal, Hanmi gives up olmutinib

    14 Apr 2018

    // John Carroll ENDPTS

    https://endpts.com/after-patient-deaths-failed-partnerships-and-a-stock-scandal-hanmi-finally-gives-up-on-controversial-olmutinib-what-did-we-learn/

    John Carroll ENDPTS
    14 Apr 2018
    Share Share
    Hanmi Pharma gives up on development of lung cancer drug Olita
    Hanmi Pharma gives up on development of lung cancer drug Olita

    12 Apr 2018

    // Kim Da-sol KOREAHERALD

    http://www.koreaherald.com/view.php?ud=20180413000635

    Kim Da-sol KOREAHERALD
    12 Apr 2018
    Share Share